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ABSTRACT
The human malignant mesothelioma (HMM) is characterized by a chemoresistant 
and immunosuppressive phenotype. An effective strategy to restore chemosensitivity 
and immune reactivity against HMM is lacking. We investigated whether the use of 
zoledronic acid is an effective chemo-immunosensitizing strategy.
We compared primary HMM samples with non-transformed mesothelial cells.
HMM cells had higher rate of cholesterol and isoprenoid synthesis, constitutive 
activation of Ras/extracellular signal-regulated kinase1/2 (ERK1/2)/hypoxia 
inducible factor-1α (HIF-1α) pathway and up-regulation of the drug efflux transporter 
P-glycoprotein (Pgp). By decreasing the isoprenoid supply, zoledronic acid down-
regulated the Ras/ERK1/2/HIF-1α/Pgp axis and chemosensitized the HMM cells to 
Pgp substrates. The HMM cells also produced higher amounts of kynurenine, decreased 
the proliferation of T-lymphocytes and expanded the number of T-regulatory (Treg) 
cells. Kynurenine synthesis was due to the transcription of the indoleamine 1,2 
dioxygenase (IDO) enzyme, consequent to the activation of the signal transducer 
and activator of transcription-3 (STAT3). By reducing the activity of the Ras/ERK1/2/
STAT3/IDO axis, zoledronic acid lowered the kyurenine synthesis and the expansion 
of Treg cells, and increased the proliferation of T-lymphocytes.
Thanks to its ability to decrease Ras/ERK1/2 activity, which is responsible 
for both Pgp-mediated chemoresistance and IDO-mediated immunosuppression, 
zoledronic acid is an effective chemo-immunosensitizing agent in HMM cells.
INTRODUCTION
Human malignant mesothelioma (HMM) is an 
asbestos-related tumor with a progressively increasing 
incidence in the next 10 years. The current therapy is based 
on pleuro-pneumonectomy, neo-adjuvant and/or adjuvant 
chemotherapy, radiotherapy [1]. The prognosis is poor 
and the overall survival is less than 1 year. Small phase I/
II trials using targeted therapy - e.g. inhibitors of vascular 
endothelial growth factor receptor, phosphatidylinositol 
3-kinase/mammalian target of rapamycin (PI3K/
mTOR), histone deacetylase and proteasome [2–4] -, 
employing gene therapy [5] or immunotherapy [3, 6, 7], 
are ongoing. These approaches however do not offer 
significant advantages in terms of patients’ outcome, 
and chemotherapy is still the most common therapeutic 
approach. The first-line chemotherapy is based on platinum 
salts and antifolates (such as pemetrexed or ralitrexed) [3]; 
multiple combinations of drugs, including mitomycin C, 
Vinca alkaloids, gemcitabine, anthracyclines, irinotecan 
[2], have been experimented as second-line treatments, with 
poor success.
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The main reasons of the chemotherapy failure 
include the scanty drug delivery within pleural tissue 
and the chemoresistance, which occurs in up to 60% of 
the HMM patients at the diagnosis [8]. The activation 
of PI3K/Akt/mTOR [9, 10], osteopontin/Akt [11], 
macrophage colony stimulating factor-1 receptor/
Akt [12], Mcl-1/Bcl-xL [13], senescence-associated 
secretory phenotype/signal transducer and activator 
of transcription-3 (STAT3) [14] pathways, and the 
presence of the ATP binding cassette (ABC) transporters 
P-glycoprotein (Pgp), multidrug resistance related proteins 
(MRPs) and breast cancer resistance protein (BCRP) [10, 
15–17], have been correlated with HMM chemoresistance. 
Pgp has the broadest spectrum of substrates, which 
include anthracyclines, taxanes, Vinca alkaloids, 
epipodophyllotoxins, topotecan, methotrexate, imatinib, 
dasatinib, lapatinib, gefitinib, sorafenib, erlotinib [18].
The second issue that makes HMM hard to eradicate 
is the tumor-induced immunosuppression [7], mainly due to 
the release of specific cytokines increasing the percentage 
of immunosuppressive regulatory T-cells (Tregs) [19], 
myeloid-derived suppressor cells, type 2-tumor associated 
macrophages (TAMs), which suppress the proliferation and 
effector functions of T-lymphocytes [7].
One of the strongest mediators of tumor-induced 
immunosuppression is kynurenine, a tryptophan catabolite 
produced by indoleamine 1,2 dioxygenase (IDO) [20]. The 
role of kynurenine in HMM has not yet been investigated.
The “ideal” therapy of HMM should improve the 
efficacy of chemotherapy and recover the immunosuppression 
induced by the HMM cells themselves.
Recently we demonstrated that the aminobisphos-
phonate zoledronic acid overcomes the resistance 
to doxorubicin by reducing the activity of Ras/
extracellular signal-regulated kinase1/2 (ERK1/2)/
hypoxia inducible factor-1α (HIF-1α)/Pgp axis, and 
restores a proper recognition by the host immune 
system in chemo-immunoresistant solid tumors [21]. 
Zoledronic acid is known to reduce HMM growth [22], 
induce apoptosis [23], up-regulate p53 [24], impair the 
polarization of TAMs towards type 2-phenotype, reduce 
the synthesis of immunosuppressive cytokines [25].
In this work we investigated whether the use of 
zoledronic acid is an effective chemo-immunosensitizing 
strategy in primary HMMs, thus fulfilling two 
requirements of the “ideal” therapy of HMM.
RESULTS
Zoledronic acid chemosensitizes mesothelioma 
cells by down-regulating the Ras/ERK1/2/ 
HIF-1α/Pgp axis
Samples from ten HMM patients, whose 
demographic and histological features are reported in 
Table 1, were analyzed for the sensitivity to different 
chemotherapeutic drugs, unrelated for chemical structure 
and activity: irrespectively of the patients’ clinical 
and histological features, the half maximal inhibitory 
concentration (IC50) for each drug (Table 2) and the 
resistance factor (Rf; Table 3) were significantly higher 
than in non-transformed human mesothelial cells (HMC).
All HMM samples expressed Pgp, MRP1 and 
MRP3, and showed variable amounts of MRP4, MRP5, 
BCRP; such ABC transporters were undetectable in HMC 
(Supplementary Figure 1). In the subsequent experiments, all 
the 10 samples (indicated as HMM cells) were investigated, 
but in blotting experiments, for sake of simplicity, we show 
four out of the ten samples, including one sarcomatous, two 
epithelioid (one SV-40-negative and one SV-40-positive) and 
one biphasic histotypes. However, no significant differences 
in the parameters examined were observed as a function of 
the histotype (see below). Compared to the HMC, the HMM 
Table 1: Demographic and histological features of HMM patients
UPN Age Sex Histotype Asbestos exposure SV40 presence
1 79 M Epithelioid Unlikely Negative
2 60 M Biphasic Professional Negative
3 68 M Epithelioid Professional Negative
4 64 M Epithelioid Not determined Negative
5 70 M Epithelioid Professional Negative
6 80 F Sarcomatous Environmental Negative
7 89 F Sarcomatous Not determined Negative
8 72 M Biphasic Not determined Negative
9 62 M Epithelioid Professional Positive
10  66  F Sarcomatous Not determined Negative
UPN: unknown patient number
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cells had higher cholesterol and farnesyl pyrophosphate 
(FPP) synthesis (Figure 1a), and showed higher levels of 
GTP-bound Ras (Figure 1b), phosphorylation (Figure 1b) 
and activity (Figure 1c) of the Ras downstream effectors 
ERK1/2. In HMM cells, but not in HMC, the transcription 
factor HIF-1α, a known inducer of Pgp and a target of Ras/
ERK1/2 axis [21], was phosphorylated on serine (Figure 1d), 
translocated in the nucleus (Figure 1e) and bound to the 
target DNA (Figure 1f). By inhibiting the FPP synthase [26] 
and reducing the FPP supply (Figure 1a) necessary for Ras, 
zoledronic acid significantly lowered the activation of Ras, 
ERK1/2 and HIF-1α (Figures 1b–f).
HIF-1α was constitutively bound to the promoter 
of MDR1 gene, which encodes for Pgp, in HMM 
cells (Figure 2a) that – differently from HMC – were 
characterized by constitutively detectable levels of Pgp 
protein (Figure  2b). Zoledronic acid reduced the binding 
of HIF-1α to the MDR1 promoter (Figure 2a) and the 
Table 2: IC50 (µmol/L) of different chemotherapeutic drugs in HMC and HMM cells
Sample DOX VBL ETO Pt GEM PMX MXR
HMC 4.3 ± 0.12 5.5 ± 0.02 52.00 ± 6.32 9.09 ± 1.39 4.46 ± 0.82 0.89 ± 0.05 17.87 ± 1.57
UPN 1 30.05 ± 1.32 36.32 ± 0.13 169.27 ± 12.33 49.01 ± 5.21 28.06 ± 2.54 5.14 ± 0.89 90.97 ± 4.21
UPN 2 30.05 ± 2.38 39.45 ± 0.25 204.79 ± 12.41 57.47 ± 1.23 38.42 ± 2.36 6.00 ± 1.01 111.19 ± 9.56
UPN 3 31.57 ± 5.26 47.66 ± 0.51 247.58 ± 14.58 99.99 ± 4.36 50.97 ± 4.15 9.06 ± 1.58 123.55 ± 4.2
UPN 4 25.98 ± 2.56 33.68 ± 0.24 174.61 ± 9.63 53.19 ± 5.23 25.75 ± 4.23 7.22 ± 0.57 105.34 ± 8.21
UPN 5 59.38 ± 5.69 44.43 ± 0.16 230.39 ± 12.14 108.68 ± 4.23 50.97 ± 5.36 7.33 ± 1.02 238.27 ± 14.85
UPN 6 22.88 ± 4.23 33.32 ± 0.24 172.79 ± 5.23 58.82 ± 2.36 28.38 ± 1.28 5.42 ± 0.47 115.03 ± 11.03
UPN 7 28.02 ± 2.59 33.19 ± 0.16 165.88 ± 6.32 52.63 ± 4.51 26.86 ± 1.95 5.80 ± 0.12 149.36 ± 8.25
UPN 8 27.11 ± 1.06 33.51 ± 0.12 182.29 ± 11.04 54.94 ± 7.23 28.71 ± 1.87 5.60 ± 0.43 108.77 ± 5.23
UPN 9 28.02 ± 0.28 33.16 ± 0.17 164.24 ± 12.54 52.63 ± 1.45 26.86 ± 2.54 5.80 ± 0.62 181.95 ± 14.5
UPN 10 47.96 ± 8.72 44.76 ± 0.41 247.58 ± 11.32 68.49 ± 5.28 44.60 ± 1.23 10.60 ± 0.74 181.99 ± 5.48
HMC: human mesothelial cells; HMM: human malignant mesothelioma; UPN: unknown patient number; DOX: 
doxorubicin; VBL: vinblastine; ETO: etoposide; Pt: cisplatin; GEM: gemcitabine; PMX: pemetrexed; MXR: mitoxantrone. 
Significance for each drug, HMM cells versus HMC: p < 0.01.
Table 3: Resistance factor (Rf) for different chemotherapeutic drugs in HMM cells
DOX VBL ETO Pt GEM PMX MXR
UPN 1 6.99 5.92 5.11 5.39 6.29 5.77 5.09
UPN 2 6.99 7.16 6.08 6.32 8.62 6.75 6.22
UPN 3 7.34 8.66 6.86 11 11.43 10.18 6.91
UPN 4 6.04 6.11 4.62 5.85 5.77 8.12 5.89
UPN 5 13.81 8.06 7.62 11.96 11.43 8.24 13.33
UPN 6 5.32 6.04 5.39 6.47 6.36 6.09 6.44
UPN 7 6.52 5.8 5.22 5.79 6.02 6.51 8.36
UPN 8 6.3 6.37 5.27 6.04 6.44 6.29 6.09
UPN 9 6.52 5.74 5.22 5.79 6.02 6.51 10.18
UPN 10 11.15 8.66 7.62 7.53 10 11.91 10.18
Resistance factor (Rf) was calculated by dividing the IC50 of each drug in human malignant mesothelioma HMM cells for 
the corresponding IC50 in human mesothelial cells HMC (see Table 2).
UPN: unknown patient number; DOX: doxorubicin; VBL: vinblastine; ETO: etoposide; Pt: cisplatin; GEM: gemcitabine; 
PMX: pemetrexed; MXR: mitoxantrone.
Significance for each drug. HMM cells versus HMC: p < 0.001.
Oncotarget1131www.impactjournals.com/oncotarget
Figure 1: Zoledronic acid down-regulates Ras/ERK1/2/HIF-1α axis in mesothelioma cells. HMC and HMM cells (UPN, 
unknown patient number) were incubated in fresh medium (-) or in the presence of 1 μmol/L zoledronic acid (ZA) for 48 h, then subjected to 
the following investigations. (a) The cells were radiolabeled during the last 24 h with [3H]acetate, then the de novo synthesis of cholesterol 
(open bars) or FPP (solid bars) was measured as described in Materials and methods. Data are presented as means ± SD (n = 3). Vs untreated 
(-) cells: *p < 0.01; HMM cells vs HMC: °p < 0.005. (b) The cells were lysed and subjected to the Western blot analysis for Ras-GTP (as index 
of active Ras), total Ras, phospho(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2, total ERK1/2. The β-tubulin expression was used as control of 
equal protein loading. The figure is representative of 3 experiments with similar results. (c) The ERK activity was measured in cell lysates by a 
specific ELISA kit. Data are presented as means ± SD (n = 3). Vs untreated (-) cells: *p < 0.01; HMM cells vs HMC: °p < 0.01. (d) Cells were 
lysed and subjected to the Western blot analysis for phospho(Ser)-HIF-1α and total HIF-1α. The β-tubulin expression was used as control of 
equal protein loading. The figure is representative of 3 experiments with similar results. (e) The amount of HIF-1α was measured in nuclear 
extracts by Western blotting. The TBP expression was used as control of equal protein loading. The figure is representative of 3 experiments 
with similar results. (f) HIF-1α activity was measured in nuclear extracts by a specific ELISA kit. For each set of experiments, a competition 
assay (using 20 pmol of the wild type oligonucleotide with nuclear extracts from UPN1 cells grown at 3% O2 for 24 h) was included. In 
hypoxic conditions, the activity of HIF-1α was 58.32 ± 7.97 U/mg proteins; in the competition assay, the corresponding HIF-1α activity 
was reduced to 5.09 ± 0.56 U/mg proteins (n = 3; p < 0.001). Data are presented as means ± SD (n = 3). Vs untreated (-) cells: *p < 0.01; 
HMM cells vs HMC: °p < 0.001.
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Figure 2: Zoledronic acid chemosensitizes mesothelioma cells to Pgp substrates. HMC and HMM cells (UPN, unknown patient 
number) were incubated in fresh medium (-) or in the presence of 1 μmol/L zoledronic acid (ZA) for 48 h, then subjected to the following 
investigations. (a) ChIP of HIF-1α on MDR1 promoter (pro MDR1). wo Ab: samples precipitated without anti-HIF-1α antibody; bl: blank; 
input: genomic DNA. The figure is representative of 3 experiments with similar results. (b) Cells were lysed and subjected to the Western 
blot analysis for Pgp expression. The β-tubulin expression was used as control of equal protein loading. The figure is representative of 
3 experiments with similar results. (c) IC50 for doxorubicin, vinblastine, etoposide, cisplatin, gemcitabine and pemetrexed in HMM cells. The 
cells were incubated with increasing concentrations of each drug (1-10-100 pmol/L, 1-10-100 nmol/L, 1-10-100 μmol/L, 1 mmol/L) for 48 h, 
in the absence (CTRL) or in the presence of 1 μmol/L ZA. Cell viability was assessed with neutral red staining, as detailed under Materials and 
methods. Data are presented as means ± SD (n = 4). Doxorubicin-, vinblastine-, etoposide-treated cells vs CTRL cells: *p < 0.02.
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expression of Pgp (Figure 2b). Consequently, it lowered 
the IC50 of chemotherapeutic drugs that are substrates 
of Pgp (Supplementary Table 1), such as doxorubicin, 
vinblastine and etoposide (Figure 2c). By contrast, 
zoledronic acid did not affect the IC50 of cisplatin, 
gemcitabine and pemetrexed (Figure 2c) that are not 
effluxed by Pgp (Supplementary Table 1).
The mean IC50 of zoledronic acid alone in 
HMM samples was 96.3 ± 8.7 μmol/L, nearly 100-fold 
higher than the concentration (1 μmol/L) used in all 
our experiments. Such difference led to exclude that 
zoledronic acid exerts a cytotoxic effect in HMM cells at 
the concentration used in the present work.
The combination index (CI) of 1 μmol/L zoledronic 
acid and different concentrations (from 1 pmol/L to 
1 mmol/L) of chemotherapeutic drugs is reported in 
the Supplementary Table 2 and in the Supplementary 
Figure 2: whereas for most concentrations of doxorubicin, 
vinblastine and etoposide the effect of zoledronic acid 
was synergistic, for most concentrations of cisplatin, 
gemcitabine and pemetrexed the effect was additive 
(Supplementary Figure 2). Focusing on the concentrations 
around the IC50 of each chemotherapeutic drug in 
the presence of zoledronic acid, we found that the 
aminobisphosphonate produced clear synergistic effects 
in the case of doxorubicin, vinblastine and etoposide, 
additive effects or even slightly antagonistic effects 
in the case of cisplatin, gemcitabine and pemetrexed 
(Supplementary Table 2).
As shown in the Supplementary Table 1, ABC 
transporters other than Pgp mediate the resistance towards 
cisplatin, gemcitabine and pemetrexed. Differently 
from what observed on Pgp levels, zoledronic acid 
did not reduce the expression of MRP1, MRP2, MRP4 
and MRP5 (Supplementary Figure 3a), the transporters 
involved in the efflux of cisplatin, gemcitabine and 
pemetrexed (Supplementary Table 1). The amount of 
cisplatin, gemcitabine and pemetrexed retained within 
HMM cells was sufficient to exert the typical anti-tumor 
actions of these drugs. Cisplatin induced DNA damage 
(Supplementary Figure 3b). Gemcitabine impaired the 
cell cycle progression by increasing the percentage 
of apoptotic cells and of cells blocked in S-phase, thus 
inducing a mitotic catastrophe (Supplementary Figure 3c). 
Pemetrexed inhibited the target enzyme dihydrofolate 
reductase (DHFR; Supplementary Figure 3d). As to 
all these parameters, however, zoledronic acid did 
not enhance the anti-tumor effects induced by the 
chemotherapeutic drugs (Supplementary Figure 3b–d).
Zoledronic acid immunosensitizes mesothelioma 
cells by lowering the expression and activity of 
IDO in a Ras/ERK1/2/STAT3-dependent way
Primary HMM cells exhibited higher synthesis 
of the IDO-derived immunosuppressive mediator 
kynurenine, higher levels of IDO mRNA and protein than 
HMC, all reduced by zoledronic acid (Figures 3a–b).
Moreover, HMC stimulated T-lymphocyte 
proliferation more than HMM cells, but zoledronic 
acid-treated HMM cells significantly increased T-cell 
proliferation (Figure 3c). The percentages of CD3+ 
T-cells, CD4+ T-helper cells, CD8+ T-cytotoxic cells did 
not differ between HMC and HMM cells, both with or 
without zoledronic acid (Supplementary Figure 4a–c). 
Interestingly, the HMM cells expanded the number 
of Tregs, and zoledronic acid counteracted this event 
(Figure 3d). The IDO inhibitor 5-Br-brassinin [27], which 
actually decreased the activity of IDO in HMM cells 
(Supplementary Figure 5a), caused a response similar to 
zoledronic acid (Supplementary Figure 5b–c), suggesting 
that high kynurenine levels were accompanied by reduced 
T-lymphocyte proliferation and higher Tregs expansion, 
whereas low kynurenine levels – induced by zoledronic acid 
or 5-Br-brassinin – were paralleled by an opposite scenario.
The transcriptional activators of the IDO gene 
STAT1 and STAT3 [28, 29] were present in HMM cells and 
constitutively translocated in the nucleus (Figure  4a). To 
investigate their involvement in the transcription of IDO, 
STAT1 and STAT3 were separately silenced in two primary 
HMM samples (one epithelioid and one sarcomatous; 
Figure 4a). STAT3-, but not STAT1-silenced cells showed 
decreased IDO mRNA (Figure 4b) and activity (Figure 4c).
The phosphorylation of STATs on tyrosine [30] and 
serine [31, 32] is critical for their transcriptional activity. 
In HMM cells STAT1 was constitutively phosphorylated 
on tyrosine 701 and serine 727, STAT3 was constitutively 
phosphorylated on tyrosine 705 and serine 727 (Figure 4d). 
Zoledronic acid specifically reduced the phosphorylation 
of STAT3 on serine 727 (Figure 4d).
Since Ras/ERK1/2 axis is involved in the serine 
phosphorylation of STAT3 [33, 34], we next investigated 
whether the zoledronic acid’s effect was mediated by 
the down-regulation of Ras and ERK1/2 activity. To this 
aim, we produced two HMM clones (one epithelioid and 
one sarcomatous) stably and inducibly silenced for Ras: 
both clones showed decreased expression of Ras and 
phosphorylation of ERK1/2 (Figure 5a). The same clones 
were also incubated with the ERK1/2 inhibitor PD98059, 
used as second tool to block the Ras/ERK1/2 pathway. 
Compared to parental cells, both Ras-silenced and PD98059-
treated cells showed lower ERK activity (Figure 5b), 
reduced levels of phospho(Ser727)-STAT3 without changes 
in phospho(Tyr705)-STAT3 or total STAT3 (Figure 5c), 
lower IDO activity and mRNA (Figure 5d), reproducing the 
situation observed in HMM cells treated with zoledronic acid.
DISCUSSION
In this work we found that the aminobisphosphonate 
zoledronic acid reverses chemoresistance and 
immunosuppression of HMM cells.
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Since HMM patients vary for genetic aberrations, 
histological features, absence or presence of pro-
oncogenic factors, we collected a series of HMM primary 
samples, homogeneous for the demographic features, 
but different for the tumor histotype and etiology. One 
epithelioid sample contained SV40 whole genome, which 
has been related to a highly aggressive phenotype [35]. 
All samples had a multidrug resistant phenotype and 
were significantly more chemoresistant than the non-
transformed HMC, owing to the constitutive presence of 
several ABC transporters.
As it occurs in other chemoresistant cells [21], the 
HMM cells displayed a higher synthesis of cholesterol and 
isoprenoid units like FPP, and a higher activity of Ras and 
downstream effectors implicated in the chemoresistance 
[21], compared to the chemosensitive HMC. Ras/ERK1/2 
axis is a critical pro-oncogenic pathway in HMM [36]. It 
has been reported that HMM cells silenced for ERK1/2 are 
more sensitive to doxorubicin and have a lower expression 
of Pgp [37]: our results provide an explanatory mechanism 
for this observation, showing that Pgp transcription is 
sustained by the Ras/ERK1/2/HIF-1α axis in this tumor.
Figure 3: Zoledronic acid down-regulates IDO expression in mesothelioma cells and inhibits the tumor-induced 
immunosuppression. HMC and HMM cells (UPN, unknown patient number) were incubated in fresh medium (-) or in the presence of 
1 μmol/L zoledronic acid (ZA) for 48 h, then subjected to the following investigations. (a) The kynurenine level in cells culture supernatant, 
taken as an index of IDO enzymatic activity, was measured fluorimetrically (open bars, act); the expression levels of IDO mRNA were 
measured by qRT-PCR (solid bars, mRNA). Data are presented as means ± SD (n = 4). Vs untreated (-) cells: *p < 0.01; HMM cells vs 
HMC: °p < 0.002. (b) The cells were lysed and subjected to Western blot analysis for IDO expression. The β-tubulin expression was used 
as control of equal protein loading. The figure is representative of 3 experiments with similar results. (c) The proliferation of activated 
T-lymphocytes collected from PBMC after a 72 h co-incubation with HMC and HMM cells, grown in fresh medium (-) or in medium 
containing 1 μmol/L ZA, was measured with the [3H]thymidine assay. As positive control of proliferation, the PBMC were treated with 
the anti-CD3 and anti-CD28 antibodies, in the absence of cells; as negative control, the PBMC were grown in RPMI-1640 medium, in the 
absence of anti-CD3 and anti-CD28 antibodies, and of cells. In the presence of the anti-CD3 and anti-CD28 stimulatory antibodies, the [3H]
thymidine incorporation was 33,123 ± 3,256 cpm; in the presence of RPMI-1640 medium alone, the [3H]thymidine incorporation was 3,892 
± 297 cpm. The [3H]thymidine incorporation in HMC and HMM cells were: 480 ± 190 cpm (untreated HMC); 482 ± 44 cpm (ZA-treated 
HMC); 485 ± 277 cpm (untreated HMM cells); 289 ± 28 cpm (ZA-treated HMM cells). Data are presented as means ± SD (n = 3). HMM 
cells vs HMC: *p < 0.01; ZA-treated HMM cells vs untreated (-) cells: °p < 0.05. (d) The percentage of Tregs (CD4+CD25+CD127low) 
collected from PBMC, co-incubated as reported in c, was measured by flow cytometry. Data are presented as means ± SD (n = 3). HMM 
cells vs HMC: *p < 0.02; ZA-treated HMM cells vs untreated (-) cells: °p < 0.05.
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Zoledronic acid, which inhibited the Ras/
ERK1/2/HIF-1α/Pgp pathway, induced an appreciable 
chemosensitization of HMM cells. Such effect was 
specifically linked to the decrease of Pgp. Zoledronic 
acid indeed decreased the expression of Pgp, allowing 
Pgp substrates – such as doxorubicin, vinblastine and 
Figure 4: Zoledronic acid reduces the phosphorylation of STAT3, which is critical to up-regulate IDO in mesothelioma 
cells. HMM samples (UPN: unknown patient number) were grown for 24 h in fresh medium (-), treated with a non-targeting scrambled 
siRNA (scr) or with a specific siRNA pool targeting STAT1 or STAT3 (siSTAT1, siSTAT3). (a) The expression of STAT1 and STAT3 was 
measured in whole cell lysates (left panel) and in nuclear extracts (right panel) by Western blotting. The β-tubulin and TBP expression 
were used as controls of equal protein loading in whole cell lysates and nuclear extracts, respectively. The figure is representative of 
3 experiments with similar results. (b) The expression levels of IDO mRNA were measured by qRT-PCR. Data are presented as means ± 
SD (n = 4). Vs untreated (-) cells: *p < 0.001. (c) The kynurenine level in the cell culture supernatant, taken as an index of IDO enzymatic 
activity, was measured fluorimetrically. Data are presented as means ± SD (n = 4). Vs untreated (-) cells: *p < 0.001. (d) The cells were 
grown in fresh medium (-) or in the presence of 1 μmol/L zoledronic acid (ZA) for 48 h, then lysed and subjected to the Western blot analysis 
of phospho(Tyr701)-STAT1, phospho(Ser727)-STAT1, total STAT1, phospho(Tyr705)-STAT3, phospho(Ser727)-STAT3, total STAT3. The 
β-tubulin expression was used as control of equal protein loading. The figure is representative of 3 experiments with similar results.
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etoposide – to reach higher intracellular accumulation 
and toxicity. On the other hand, we did not observe any 
sensitization towards substrates of other ABC transporters, 
such as cisplatin, gemcitabine and pemetrexed. This 
can be due to the lack of down-regulation of the ABC 
transporters that extrude these drugs, and/or to the lack 
of effects on the classical cellular targets of cisplatin, 
gemcitabine and pemetrexed. These factors may explain 
the different pharmacological profile (i.e. synergistic 
versus additive/antagonistic effects) between substrates 
and non-substrates of Pgp in the presence of zoledronic 
acid. Although Pgp substrates are not included in the first-
line therapy of HMM, most of them are used in second-
line protocols [2–4]: reducing the Pgp amount is important 
to improve the therapeutic efficacy of either conventional 
chemotherapeutic drugs or new targeted drugs effluxed 
by this transporter [18]. The concentration of zoledronic 
acid that we used was not toxic and was compatible with 
Figure 5: Effects of Ras/ERK1/2 inhibition on STAT3 phosphorylation and IDO expression in mesothelioma cells. HMM 
samples (UPN: unknown patients number), treated with a TetON vector containing a shRNA for RAS (sh) or with the ERK1/2 inhibitor 
PD98059 (10 μmol/L for 24 h, PD), were cultured in medium without (-) or with (+) 1 μg/mL doxycycline (doxy). After 24 h, the following 
investigations were performed. (a) The expression of Ras, phospho(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2, total ERK1/2 was measured 
in whole cell lysates by Western blotting. The β-tubulin expression was used as control of equal protein loading. The figure is representative 
of 3 experiments with similar results. (b) The ERK activity was measured in cell lysates using a specific ELISA kit. Data are presented 
as means ± SD (n = 3). Vs untreated (doxy -, PD -) cells: *p < 0.001. (c) The expression of phospho(Tyr705)-STAT3, phospho(Ser727)-
STAT3, total STAT3 was assessed in whole cell lysates by Western blotting. The β-tubulin expression was used as control of equal protein 
loading. The figure is representative of 3 experiments with similar results. (d) The relative expression levels of IDO mRNA were measured 
by qRT-PCR (open bars, mRNA); the kynurenine level in cell culture supernatant, taken as an index of IDO enzymatic activity, was 
measured fluorimetrically (solid bars, act). Data are presented as means ± SD (n = 4). Vs untreated (doxy -, PD -) cells: *p < 0.005.
Oncotarget1137www.impactjournals.com/oncotarget
the blood concentration observed in patients [38], making 
zoledronic acid potentially applicable to clinical protocols 
for HMM in association with chemotherapy.
Besides chemoresistance, the tumor-induced 
immunosuppression makes HMM an aggressive 
tumor. The role of the immunosuppressive metabolite 
kynurenine, as well as the molecular pathways up-
regulating the kynurenine producing enzyme IDO, 
has not been investigated in HMM. We found that 
kynurenine production and IDO expression were 
significantly higher in HMM cells than in HMC, 
leading to hypothesize that the increase of IDO and the 
immunosuppressive phenotype are associated with the 
malignant transformation of mesothelium. The higher 
IDO activity was paralleled by the reduced proliferation 
of T-lymphocytes and by the increased expansion of 
the immunosuppressive Tregs subpopulation. Of note, 
zoledronic acid, which down-regulated IDO, restored 
the proliferation of T-lymphocytes and decreased the 
expansion of Tregs. The increased number of Tregs 
has been previously related to the HMM-induced 
immunosuppression [19, 39], but not to the production 
of kynurenine. These data are the premise to our in 
progress studies in immunocompetent animal models, 
aimed at investigating whether kynurenine is the 
actual responsible for the Tregs expansion and for the 
mesothelioma-induced immunosuppression in vivo.
Since mitogen-activated protein (MAP) kinases may 
activate STAT proteins [33, 34], which in turn induce IDO 
transcription [28, 29], we next investigated if in HMM 
cells – that exhibit a constitutively active Ras/ERK1/2 
axis – IDO was induced by STAT activity and if zoledronic 
acid interfered with it. Both STAT1 and STAT3 were 
activated in untreated HMM cells, in line with previous 
reports [40]. The transient silencing of STAT1 and STAT3 
suggested that only the latter was the transcriptional 
activator of IDO in HMM. Whereas Janus kinases-1 and -2 
promote the phosphorylation of STAT3 on tyrosine, MAP 
kinases induce the phosphorylation on serine [33]. STAT3 
is a good substrate for ERK1/2 kinases [41], which promote 
the transcriptional activity of STAT3 [42]. Zoledronic acid 
reduced the phosphorylation of STAT3 on serine 727. Of 
note, Ras-silenced and ERK1/2-inhibited HMM clones 
showed decreased levels of phospho(Ser727)-STAT3, 
IDO transcription and kynurenine synthesis. This pattern 
reproduced the changes elicited by zoledronic acid, 
suggesting that aminobisphosphonate counteracts the 
HMM-induced production of kynurenine by inhibiting the 
Ras/ERK1/2/STAT3 axis. The decrease of STAT3 activity 
has been exploited in vitro and in vivo as a pro-apoptotic 
strategy against HMM [43]. We suggest that lowering 
the Ras/ERK1/2/STAT3 axis can be also an effective 
immunosensitizing strategy.
In summary, we propose that the constitutively 
active Ras/ERK1/2 axis may determine both the 
chemoresistance and the immunosuppression observed 
in HMM. By phosphorylating and activating HIF-1α, this 
axis promotes the up-regulation of Pgp, which effluxes 
several chemotherapeutic drugs. By phosphorylating and 
activating STAT3, it favors the synthesis of kynurenine, 
which is paralleled by the reduced proliferation of 
T-lymphocytes and by the increased expansion of the 
pro-immunosuppressive Tregs population. Thanks to its 
ability to decrease isoprenoid synthesis and Ras/ERK1/2 
activity, zoledronic acid reverses the chemoresistance 
to Pgp substrates, lowers the kynurenine synthesis and 
the Tregs proliferation, and restores the proliferation of 
T-lymphocytes co-cultured with HMM cells (Figure 6).
By overcoming the main defects of HMM 
therapy – i.e. the poor efficacy of chemotherapy and the 
tumor-induced immunosuppression – zoledronic acid 
may represent a promising adjuvant drug for the future 
treatment protocols of HMM.
MATERIALS AND METHODS
Chemicals
The plasticware for cell cultures was from Falcon 
(Becton Dickinson, Franklin Lakes, NJ). Zoledronic 
acid was a gift from Novartis (Basel, Switzerland). 
Doxorubicin, vinblastine, etoposide, cisplatin, 
gemcitabine, pemetrexed, mitoxantrone, PD98059 were 
purchased from Sigma Chemicals Co. (St. Louis, MO). 
The electrophoresis reagents were obtained from Bio-
Rad Laboratories (Hercules, CA). The protein content of 
cell lysates was assessed with the BCA kit from Sigma 
Chemicals Co. When not otherwise specified, all the other 
reagents were purchased from Sigma Chemicals Co.
Cells
The non-transformed HMC were isolated from 
three patients with transudative pleural fluid due to 
congestive heart failure, with no history of malignant 
disease. The mesothelial origin of the isolated cells was 
confirmed by the positive immunostaining with anti-
cytokeratins 8 and 18 (Becton Dickinson), anti-vimentin 
(Dako, Glostrup, Denmark), anti-mesothelial cell (Dako) 
antibodies. The primary HMM cells were collected from 
the Biologic Bank of Malignant Mesothelioma, S.S. 
Antonio e Biagio Hospital, Alessandria, Italy, where the 
histological characterization was performed. One sample, 
already described in [35], was positive for SV40 virus. 
The samples, collected after informed written consent, 
were indicated with an “Unknown Patient Number” 
(UPN) in the manuscript. The experimental protocol was 
approved by the Bioethics Committee (“Comitato Etico 
Interaziendale”) of the S.S. Antonio e Biagio Hospital, 
Alessandria, Italy.
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Figure 6: Zoledronic acid induces chemo-immunosensitization in mesothelioma cells by downregulating the Ras/
ERK1/2/HIF-1α/Pgp and Ras/ERK1/2/STAT3/IDO axes. HMM cells have the Ras small GTPase (Ras GTP) and the downstream 
effectors ERK1/2 kinases (pERK1/2) in a constitutively active form. ERK1/2 kinases phosphorylate on serine the transcription factor HIF-1α 
(pHIF1α), which is primed to translocate in the nucleus and to increase the transcription of the MDR1 gene, which is translated into 
Pgp, an efflux transporter of chemotherapeutic drugs (D). Moreover, ERK1/2 kinases phosphorylate STAT3 (pSerSTAT3) that activates 
the transcription of the IDO gene. The increase of kynurenine (K), a product of IDO activity during the catabolism of tryptophan (T), is 
paralleled by the decreased T-lymphocyte proliferation and by the increased expansion of the immunosuppressive Tregs subpopulation. 
These events may confer to mesothelioma a chemoresistant and immunosuppressive phenotype. By inhibiting the FPP synthase (FPPS) 
and then reducing the supply of FPP necessary to activate Ras, zoledronic acid (ZA) inhibits both the Ras/ERK1/2/HIF-1α/Pgp and the 
Ras/ERK1/2/STAT3/IDO axes, thus potentially inducing chemo-immunosensitization. Green arrow: stimulation; red line: inhibition; blue 
arrow: transmembrane diffusion or transport.
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The cells were grown in Ham’s F12 nutrient 
mixture medium, supplemented with 10% v/v fetal 
bovine serum (FBS), 1% v/v penicillin-streptomycin, 1% 
v/v L-glutamine, and were maintained in a humidified 
atmosphere at 37°C and 5% CO2.
Cell viability
100,000 cells were seeded in 96-well plates, 
treated for 48 h with chemotherapeutic agents at scalar 
concentrations (from 1 pmol/L to 1 mmol/L), then 
stained with neutral red solution as described [44]. The 
IC50, i.e. the concentration of each drug that decreased 
the cell viability by 50%, was calculated with the 
CompuSyn software (http://www.combosyn.com). The 
Rf was calculated by dividing the IC50 of each drug 
in HMM cells for the IC50 of each drug in HMC. The 
synergistic, additive or antagonistic effect of the different 
concentrations of chemotherapeutic drugs in the presence 
of 1 μmol/L zoledronic acid was calculated with the 
CI equation of Chou-Talalay [45], using the CompuSyn 
software.
Mevalonate pathway activity
The cells were labeled with 1 μCi/mL [3H]acetate 
(3600 mCi/mmol; Amersham Bioscience, Piscataway, NJ). 
The synthesis of radiolabeled cholesterol and FPP was 
measured as described [21].
Ras activation assay
The GTP-bound Ras fraction, taken as an index of 
active G-proteins [46], was measured as reported [21].
Western blotting
The cells were lysed in MLB buffer (125 mmol/L 
Tris-HCl, 750 mmol/L NaCl, 1% v/v NP40, 10% v/v 
glycerol, 50 mmol/L MgCl2, 5 mmol/L EDTA, 25 
mmol/L NaF, 1 mmol/L NaVO4, 10 μg/mL leupeptin, 
10 μg/mL pepstatin, 10 μg/mL aprotinin, 1 mmol/L 
phenylmethylsulfonyl fluoride, pH 7.5), sonicated and 
centrifuged at 13,000 x g for 10 min at 4°C. 20 μg of 
proteins from cell lysates were subjected to Western 
blotting and probed with the following antibodies: 
phospho(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2 
(Millipore, Billerica, MA); ERK 1/2 (Millipore); HIF-
1α (BD Bioscience, San Jose, CA); Pgp/ABCB1 (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA); MRP1/
ABCC1 (Abcam, Cambridge, UK); MRP2/ABCC2 
(Abcam); MRP3/ABCC3 (Santa Cruz Biotechnology 
Inc.); MRP4/ABCC4 (Abcam); MRP5/ABCC5 (Santa 
Cruz Biotechnology Inc.); BCRP/ABCG2 (Santa Cruz 
Biotechnology Inc.); IDO (Abcam); phospho(Tyr701)-
STAT1 (Cell Signaling Technology, Danvers, MA); 
phospho(Ser727)-STAT1 (Millipore); STAT1 (Thermo 
Scientific, Rockford, IL); phospho(Tyr705)-STAT3 (Cell 
Signaling Technology); phospho(Ser727)-STAT3 (Cell 
Signaling Technology); STAT3 (Thermo Scientific); 
β-tubulin (Santa Cruz Biotechnology Inc.). The proteins 
were detected by enhanced chemiluminescence (Bio-
Rad Laboratories). HIF-1α phosphorylation and nuclear 
translocation were measured as reported previously 
[21], using an anti-TATA-box binding protein (TBP) 
antibody (Santa Cruz Biotechnology Inc.) as a control 
of equal nuclear protein loading. To exclude any 
cytosolic contamination of nuclear extracts, we verified 
that β-tubulin was undetectable in nuclear samples (not 
shown).
ERK, HIF-1 and DHFR activity
The ERK activity in whole cell lysates and the 
HIF-1 activity in nuclear extracts were measured with 
the MAP kinase (ERK1/2) Activity Assay kit (Millipore) 
and with the TransAM™ HIF-1 Transcription Factor 
Assay Kit (Active Motif, La Hulpe, Belgium), following 
the manufacturer’s instructions. The activity of DHFR, a 
target enzyme of pemetrexed [47], was measured in whole 
cell lysates using the Dihydrofolate Reductase Assay kit 
(Sigma Chemical Co.), following the manufacturer’s 
instructions. The data were expressed as units/mg proteins.
Chromatin immunoprecipitation (ChIP)
ChIP experiments to measure the binding of HIF-
1α to the hypoxia responsive element of the promoter of 
MDR1 were performed as previously reported [48].
Comet assay
The genotoxic damages, taken as indexes of 
cisplatin activity, were evaluated by the Single Cell 
Gel Electrophoresis assay (Comet assay), as reported 
previously [49]. Images were quantified by the 
CometScore software (TriTek Corp., Sumerduck, VA).
Cell cycle analysis
The cell cycle distribution was analyzed as a 
parameter of gemcitabine efficacy [50]. Cells were washed 
twice with fresh PBS, incubated in 0.5 mL ice-cold ethanol 
70% v/v for 15 min, then centrifuged at 1,200 x g for 5 min 
at 4oC and rinsed with 0.3 mL of citrate buffer (50 mmol/L 
Na2HPO4, 25 mmol/L sodium citrate, 1% v/v Triton X-100), 
containing 10 μg/mL propidium iodide and 1 mg/mL 
RNAse (from bovine pancreas). After a 15 min incubation 
in the dark, the intracellular fluorescence was detected by a 
FACSCalibur flow cytometer (Becton Dickinson). For each 
analysis, 10,000 events were collected and analyzed by the 
Cell QuestPro software (Becton Dickinson).
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IDO activity
The IDO activity was determined as previously 
characterized [51].
Quantitative real time-PCR (qRT-PCR)
Total RNA was reverse-transcribed using the 
iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories). 
The qRT-PCR was performed with the iTaqTM Universal 
SYBR® Green Supermix (Bio-Rad Laboratories). The 
primer sequences were designed with the qPrimerDepot 
software (http://primerdepot.nci.nih.gov/). The relative 
quantification was performed by comparing each PCR 
product with the housekeeping PCR product (β-actin), 
using the Bio-Rad Software Gene Expression Quantitation 
(Bio-Rad Laboratories).
Immunological assays
1 × 106/mL human peripheral blood mononuclear 
cells (PBMC), isolated from buffy coats of healthy donors 
(kindly provided by Blood Bank, Città della Salute 
e della Scienza di Torino Hospital, Torino, Italy) by 
centrifugation on Ficoll-Hypaque density gradient, were 
treated with anti-CD3 (OKT3, BioLegend, San Diego, 
CA) and anti-CD28 (BioLegend) antibodies, to induce the 
specific proliferation of T-lymphocytes. Then, cells were 
co-cultured for 72 h with HMC or HMM cells, previously 
irradiated with 30 Gy for 15 min, at an effector/target 
cells ratio of 10:1. The expansion of T-lymphocytes, 
the only PBMC population able to proliferate in these 
experimental conditions, was assessed by adding 1 μCi of 
[3H]thymidine (PerkinElmer, Waltham, MA) 18 h before 
the end of the co-cultures, then harvesting the plates and 
counting the radioactivity. To analyze the lymphocyte 
phenotype after the incubation with tumor cells, the 
cells were harvested, washed and re-suspended in PBS 
containing 5% v/v FBS. A 3- and 4-color flow cytometry 
analysis was performed with the appropriate combinations 
of fluorescein isothiocyanate-, r-phycoerythrin-, 
Tricolor-, Peridinin Chlorophyll Protein Complex- or 
allophycocyanin-conjugated antibodies against CD3, 
CD4, CD8, CD25 (all from Miltenyi Biotech, Bergisch 
Gladbach, Germany) and CD127 (BioLegend). Isotype 
controls were run for each sample. The samples were read 
with a FACSCalibur flow cytometer equipped with Cell 
QuestPro software (Becton Dickinson). The use of PBMC 
from healthy donors and the experimental protocols were 
approved by the Bioethics Committee (“Comitato Etico 
Interaziendale”) of the Città della Salute e della Scienza 
di Torino Hospital, Torino, Italy.
Cell silencing
For transient silencing of STAT1 and STAT3, 
200,000 cells were transfected with 400 nmol/L of 
19–25 nucleotide non-targeting scrambled siRNAs, with 
a STAT1- or STAT3-specific siRNAs pool (Santa Cruz 
Biotechnology Inc.). To produce HMM clones stably and 
inducibly silenced for Ras, 50,000 cells were transduced 
with 2.5 μg TetOn pTRIPZ vector containing a specific 
shRNA for RAS (Thermo Scientific), then selected in 
medium containing 1 μg/mL puromycin. RAS shRNA 
was induced by adding 1 μg/mL doxycycline for 24 h. 
To verify the silencing efficacy, the cells were lysed and 
checked for the expression of STAT1, STAT3 or Ras by 
Western blotting, as described above.
Statistical analysis
All data in text and figures are provided as means ± SD. 
The results were analyzed by a one-way analysis of variance 
assay (ANOVA). p < 0.05 was considered significant.
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure 1: Expression of ABC transporters in mesothelial and mesothelioma cells. HMC and HMM cells 
(UPN, unknown patient number) were lysed and subjected to the Western blot analysis for Pgp, MRP1, MRP2, MRP3, MRP4, MRP5, 
BCRP. The β-tubulin expression was used as control of equal protein loading. The figure is representative of 3 experiments with similar 
results.
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Supplementary Figure 2: Synergistic, additive and antagonistic effects of the association of zoledronic acid and 
chemotherapeutic drugs in mesothelioma cells. HMM cells were incubated for 48 h with 1 μmol/L zoledronic acid plus 
chemotherapeutic drugs (doxorubicin, DOX; vinblastine, VBL; etoposide, ETO; cisplatin, Pt; gemcitabine, GEM; pemetrexed, PMX) in a 
range of concentrations from 1 pmol/L to 1 mmol/L. The Fa-CI plot (Chou-Talalay’s plot) was built by plotting the effect level (Fa, where 1 = 
100% effect) versus the logarithm of the combination index (CI) for each combination of chemotherapeutic drugs and zoledronic acid. Each 
point represents the mean CI obtained in all HMM samples; the corresponding numerical values are reported in the Supplementary Table 2. 
Points below the horizontal line: synergism; points on the horizontal line: additive effect; points above the horizontal line: antagonism.
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Supplementary Figure 3: Effect of zoledronic acid on ABC transporters and intracellular targets of cisplatin, 
gemcitabine and pemetrexed in mesothelioma cells. (a) HMM cells (UPN: unknown patient number) were incubated for 48 h in 
fresh medium (-) or with 1 μmol/L zoledronic acid (ZA), then lysed and subjected to the Western blot analysis for MRP1, MRP2, MRP4, 
MRP5. The β-tubulin expression was used as control of equal protein loading. The figure is representative of 3 experiments with similar 
results. (c) HMM cells were incubated for 48 h in fresh medium (-), in medium containing 1 μmol/L ZA or 50 μmol/L cisplatin (i.e. the 
mean IC50 for cisplatin; Pt), alone or in combination, then subjected to the Comet assay. Left panel: representative microphotographs of 
DNA comets in each experimental condition. The photographs are representative of independent experiments on the HMM samples of 
panel a. Bars = 10 µm. Right panel: quantitative analysis of the fluorescence microscope microphotographs. 100 tails for each experimental 
condition were analyzed. Vs untreated (-) cells: *p < 0.05. HMM cells incubated for 1 h with 100 μmol/L H2O2, chosen as inducer of DNA 
damage, had a percentage of DNA tail of 64 ± 13% (p < 0.01 vs untreated cells) (c) HMM cells were grown for 48 h in fresh medium (-), 
in medium containing 1 μmol/L ZA or 30 μmol/L gemcitabine (i.e. the mean IC50 for gemcitabine; GEM), alone or in combination. The 
cell cycle distribution was measured by flow cytometry. Data are presented as means ± SD (n = 3). Vs untreated (-) cells: *p < 0.005. (d) 
HMM cells were incubated for 48 h in fresh medium (-), in medium containing 1 μmol/L ZA or 6 μmol/L pemetrexed (i.e. the mean IC50 
for pemetrexed; PMX), alone or in combination, then lysed and analyzed for the activity of dihydrofolate reductase (DHFR). Data are 
presented as means ± SD (n = 3). Vs untreated (-) cells: *p < 0.01. HMM cells incubated for 48 h with 100 μmol/L methotrexate, chosen as 
positive control of DHFR inhibition, had an activity of 0.96 ± 0.13 U/mg proteins (n = 3; p < 0.001 vs untreated cells).
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Supplementary Figure 4: Effects of zoledronic acid on CD3+ T-cells, CD4+ T-helper cells, CD8+ T-cytotoxic cells 
expansion induced by mesothelial and mesothelioma cells. The percentage of CD3+ T-cells (panel a), CD4+ T-helper cells 
(panel b), CD8+ T-cytotoxic cells (panel c) collected from PBMC, stimulated with anti-CD3 and anti-CD28 antibodies, and co-incubated 
for 72 h with HMC and HMM cells, grown in fresh medium (-) or in medium containing 1 µmol/L zoledronic acid (ZA), was measured by 
flow cytometry. Data are presented as means ± SD (n = 3).
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Supplementary Figure 5: Effects of an IDO inhibitor on the expansion of T-lymphocytes and Tregs induced by 
mesothelioma cells. (a) HMM cells were incubated in fresh medium (-) or in the presence of the IDO inhibitor 5-Br-brassinin (100 µmol/L, 
BRA) for 72 h. HMC were used as internal control. The kynurenine level in the cell culture supernatant, taken as an index of IDO enzymatic 
activity, was measured fluorimetrically. Data are presented as means ± SD (n = 3). HMM cells vs HMC: *p < 0.001; BRA-treated HMM 
cells vs untreated (-) cells: °p < 0.005. (b) The proliferation of activated T-lymphocytes collected from PBMC after a 72 h co-incubation 
with HMC or HMM cells, grown in the absence (-) or in the presence of BRA, was measured with the [3H]thymidine assay. As positive 
control of proliferation, the PBMC were treated with the anti-CD3 and anti-CD28 antibodies, in the absence of cells; as negative control, 
the PBMC were grown in RPMI-1640 medium, in the absence of anti-CD3 and anti-CD28 antibodies, and of cells. In the presence of the 
anti-CD3 and anti-CD28 stimulatory antibodies without cells, the [3H]thymidine incorporation was 30,918 ± 1,781 cpm; in the presence of 
RPMI-1640 medium alone, the [3H]thymidine incorporation was 4,025 ± 612 cpm. Data are presented as means ± SD (n = 2). HMM cells 
vs HMC: *p < 0.01; BRA-treated HMM cells vs untreated (-) cells: °p < 0.02. (c) The percentage of Tregs (CD4+CD25+CD127low) collected 
from PBMC, co-incubated as reported in b, was measured by flow cytometry. Data are presented as means ± SD (n = 2). HMM cells vs 
HMC: *p < 0.001; BRA-treated HMM cells vs untreated (-) cells: °p < 0.001.
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Supplementary Table 1: Chemotherapeutic drugs used in the study and relative efflux
transporters
drug Transporter
doxorubicin Pgp, MRP1, MRP2, MRP3, BCRP
vinblastine Pgp, MRP1, MRP2
etoposide Pgp, MRP1, MRP2, MRP3
cisplatin MRP1, MRP2, MRP4
gemcitabine MRP5
pemetrexed MRP5
mitoxantrone BCRP, Pgp, MRP1
Supplementary Table 2: Combination index (CI) of zoledronic acid and chemotherapeutic drugs 
in HMM cells
ZA drug doX + ZA VBL + ZA ETo + ZA Pt + ZA GEM + ZA PMX + ZA
(μmol/L) (μmol/L) CI CI CI CI CI CI
1 0.000001 0.11 0.42 1.19 1.92 1.93 1.58
1 0.00001 0.79 0.52 0.92 1.74 1.75 1.03
1 0.0001 0.44 0.19 0.78 1.31 1.59 1.01
1 0.001 0.64 0.09 0.37 0.93 1.73 1
1 0.01 0.08 0.14 0.15 0.69 0.98 1.06
1 0.1 0.04 0.28 0.13 1.01 1.24 0.81
1 1 0.18 0.13 0.31 1.35 0.83 1.06
1 10 0.06 0.41 0.52 1.04 1.31 1.07
1 100 0.31 0.28 0.21 1.11 0.92 0.97
1 1000 0.46 0.43 0.14 0.71 0.86 0.93
ZA: zoledronic acid; DOX: doxorubicin; VBL: vinblastine; ETO: etoposide; Pt: cisplatin; GEM: gemcitabine; PMX: 
pemetrexed.
CI was calculated in human malignant mesothelioma HMM cells incubated for 48 h with 1 μmol/L ZA plus 
chemotherapeutic drugs in a range of concentrations from 1 pmol/L to 1 mmol/L, using the Compusyn software. 
CI < 0.10: very strong synergism; 0.10 < CI < 0.30: strong synergism; 0.30 < CI < 0.70: synergism; 0.70 < CI < 0.85: 
moderate synergism; 0.85 < CI <0.90: slight synergism; 0.90 < CI <1.10: additive effect; 1.10 < CI < 1.20: slight antagonism; 
1.20 < CI < 1.45: moderate antagonism; 1.45 < CI < 3.30: antagonism; 3.30 < CI < 10: strong antagonism; CI > 10: very 
strong antagonism. Bold values highlight the CI falling in the range of the IC50 of each drug in the presence of ZA.
